Literature DB >> 18201955

Botulinum neurotoxin: evolution from poison, to research tool--onto medicinal therapeutic and future pharmaceutical panacea.

Richard M Kostrzewa1, Juan Segura-Aguilar.   

Abstract

Botulinum neurotoxin (BoNT), for more than a hundred years, has been a recognized poisonous principle in spoiled food. As its chemical structure became unraveled, and as more knowledge was gained over its mechanism of toxicity, it became clear that BoNT had the potential to act therapeutically as a targeted toxin that could inactivate specific nerve populations, and thus achieve a therapeutic goal. BoNT has evolved over the past 25 years into a viable therapeutic, now being a first line treatment for dystonia, overtly altering the course of progression of this disorder. BoNT is used for hyperhidrosis and gustatory sweating syndrome, alleviation of pain, as a treatment for overactive bladder, achalasia and anal fissure; and it has gained popularity as a cosmetic aid. Many other possible uses are being explored. The greatest potential for BoNT may lie in its being a molecular Trojan Horse - able to carry a specific enzyme or specific drug to the inside of a cancer or other type of cell while bypassing other cells and thereby having little or no ill effect. BoNT's pharmaceutical potential is boundless.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18201955     DOI: 10.1007/bf03033911

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  55 in total

Review 1.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

2.  Muscle fiber orientation in muscles commonly injected with botulinum toxin: an anatomical pilot study.

Authors:  S Deshpande; M E Gormley; J R Carey
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 3.  The treatment of cervical dystonia with botulinum toxins.

Authors:  C L Comella
Journal:  J Neural Transm (Vienna)       Date:  2007-11-12       Impact factor: 3.575

4.  Botulinum toxin type-A in therapy of patients with anismus.

Authors:  Y Ron; Y Avni; A Lukovetski; J Wardi; D Geva; S Birkenfeld; Z Halpern
Journal:  Dis Colon Rectum       Date:  2001-12       Impact factor: 4.585

Review 5.  The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome.

Authors:  D A Glaser
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 6.  Botulinum toxin for gastrointestinal disorders: therapy and mechanisms.

Authors:  H Vittal; P F Pasricha
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

7.  Treatment of overactive bladder with botulinum toxin type B: a pilot study.

Authors:  Dennis Dykstra; Al Enriquez; Michael Valley
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2003-11-25

8.  Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study.

Authors:  Giorgio Maria; Giuseppe Brisinda; Ignazio Massimo Civello; Anna Rita Bentivoglio; Gabriele Sganga; Alberto Albanese
Journal:  Urology       Date:  2003-08       Impact factor: 2.649

Review 9.  The role of botulinum toxin in the management of head and neck cancer patients.

Authors:  Rainer Laskawi; Maik Ellies
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2007-04       Impact factor: 2.064

10.  Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure.

Authors:  G Maria; G Brisinda; A R Bentivoglio; E Cassetta; D Gui; A Albanese
Journal:  Am J Surg       Date:  2000-01       Impact factor: 2.565

View more
  10 in total

1.  Neurotransmitter vesicle release from human model neurons (NT2) is sensitive to botulinum toxin A.

Authors:  Million Adane Tegenge; Helge Böhnel; Frank Gessler; Gerd Bicker
Journal:  Cell Mol Neurobiol       Date:  2012-02-29       Impact factor: 5.046

Review 2.  Recent insights into Pasteurella multocida toxin and other G-protein-modulating bacterial toxins.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Future Microbiol       Date:  2010-08       Impact factor: 3.165

3.  Plumbagin, a novel Nrf2/ARE activator, protects against cerebral ischemia.

Authors:  Tae Gen Son; Simonetta Camandola; Thiruma V Arumugam; Roy G Cutler; Richard S Telljohann; Mohamed R Mughal; Tyson A Moore; Weiming Luo; Qian-Sheng Yu; Delinda A Johnson; Jeffrey A Johnson; Nigel H Greig; Mark P Mattson
Journal:  J Neurochem       Date:  2009-12-17       Impact factor: 5.372

4.  SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons.

Authors:  Erkan Kiris; James C Burnett; Jonathan E Nuss; Laura M Wanner; Brian D Peyser; Hao T Du; Glenn Y Gomba; Krishna P Kota; Rekha G Panchal; Rick Gussio; Christopher D Kane; Lino Tessarollo; Sina Bavari
Journal:  Neurotox Res       Date:  2015-03-18       Impact factor: 3.911

Review 5.  Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

Authors:  Brenda A Wilson; Mengfei Ho
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

6.  Rapidly optimizing an aptamer based BoNT sensor by feedback system control (FSC) scheme.

Authors:  Fang Wei; Bin Bai; Chih-Ming Ho
Journal:  Biosens Bioelectron       Date:  2011-09-20       Impact factor: 10.618

Review 7.  Botulinum toxin type A in the treatment of lower limb spasticity in children with cerebral palsy.

Authors:  Francesco C Blumetti; João Carlos Belloti; Marcel Js Tamaoki; José A Pinto
Journal:  Cochrane Database Syst Rev       Date:  2019-10-08

Review 8.  Toxin-based therapeutic approaches.

Authors:  Assaf Shapira; Itai Benhar
Journal:  Toxins (Basel)       Date:  2010-10-28       Impact factor: 4.546

9.  Sensing the deadliest toxin: technologies for botulinum neurotoxin detection.

Authors:  Petr Capek; Tobin J Dickerson
Journal:  Toxins (Basel)       Date:  2010-01-07       Impact factor: 4.546

Review 10.  OnabotulinumtoxinA for chronic migraine: a critical appraisal.

Authors:  Rubesh Gooriah; Fayyaz Ahmed
Journal:  Ther Clin Risk Manag       Date:  2015-06-29       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.